Updates
** Shares of Neumora Therapeutics NMRA.O fall 11.2% to $1.35 premarket, set to break three-day winning streak
** Johnson & Johnson JNJ.N late on Thursday scrapped trials of a depression drug similar to NMRA's navacaprant, citing lack of sufficient efficacy
** Brokerage Stifel, which was one among six joint bookrunners of NMRA's IPO in 2023, cuts rating to "hold" from "buy"
** "We had always seen the success of aticaprant... as an important source of validation for the KORA mechanism," says Stifel, referring to class of drugs known as KOR antagonists
** NMRA stock plunged about 80% in early January after experimental drug navacaprant flunked late-stage trial in depression patients
** Shares down about 90% since IPO in September 2023
(Reporting by Manas Mishra)
((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。